Advanced Search
Volume 36 Issue 2
Jul.  2019
Turn off MathJax
Article Contents

LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
Citation: LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170

Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc

doi: 10.11804/NuclPhysRev.36.02.170
Funds:  National Natural Science Foundation of China (11605232); Anhui Provincial Natural Science Foundation (1808085MA10)
  • Received Date: 2018-09-26
  • Rev Recd Date: 2019-02-15
  • Publish Date: 2019-06-20
  • Currently the 99mTc is most widely used medical radioisotope as a tracer in clinical diagnosis. The supply of the 99mTc mainly depends on the production of the 99Mo in the research reactors by irradiating High Enriched Uranium targets. The traditional production technique has disadvantages of complex process, high cost, long-distance transportation loss and the risk of nuclear weapons proliferation, etc. In addition, the number of research reactors and processing facilities are limited and most of the facilities will be decommissioned soon. Sometime the supply of 99Mo/99mTc has a problem due to unexpected reactor shutdown or planned maintenance. So, during recent years, a variety of new production techniques, such as the methods using facilities of linear/cyclotron accelerators and new types of reactors, have been proposed to restore the stable supply of 99Mo/99mTc. Starting from the current supply and demand situation of 99Mo/99mTc, this paper analyses the main problems existing in the current supply chain, and mainly introduces the principle, research progress and economic benefits of six traditional and new production technologies of 99Mo/99mTc. Following three separation and purification processes of 99Mo/99mTc, the development trend and prospect of 99Mo/99mTc production were discussed. Among them, the technology of accelerator-driven fission low-enriched-uranium solution is the key research direction in the future for no reactor, no high-enriched uranium, less radioactive waste. It is also imperative to develop and optimize the separation and purification process suitable for the production system in order to reduce the loss of 99Mo/99mTc and improve product quality. The theoretical output of the99Mo sub-critical production system driven by the deuterium-tritium fusion neutron source, designed by the Institute of Nuclear Safety Technology of the Chinese Academy of Sciences, is 27 Ci/day, which can meet the medical diagnostic needs of a province in China.
  • [1] ZHANG Xianzhong. Study and Application of New Technetium-99m Labeled ISO Nitrile Complexes[D]. Beijing:Beijing Normal University, 2002(5):8. (in Chinese) (张现忠. 新型锝-99m标记异腈类配合物的研究及其应用[D]. 北京:北京师范大学, 2002(5):8.)
    [2] XIAO Fu. Technetium-the main force in clinical nuclear medicine diagnosis. Guangdong:Radiation Protection Association of Guangdong Province[EB/OL]. 2016-06-01. http://www.gdfushefanghuxiehui.com/menberview.asp?id=2&viewid=703. (in Chinese) (小辐. 锝——临床核医学诊断中的主力军[EB/OL]. 2016-06-01. 广东省:广东辐射防护协会. http://www.gdfushefanghuxiehui.com/menberview.asp?id=2&viewid=703
    [3] SOUTO F J, KIMPLAND R H, HEGER A S. Prenatal Diagnosis, 2005, 33(6):575.
    [4] ZHANG Yan. Foreign Nuclear News, 2011(6):28. (in Chinese) (张焰. 国外核新闻, 2011(6):28.)
    [5] AHMAD M, VANDEGRIFT G, CRISTINI P. Science & Technology of Nuclear Installations, 2013, 1:3.
    [6] WU Haosong. Foreign Nuclear News, 2016(12):16. (in Chinese) (伍浩松. 国外核新闻, 2016(12):16.)
    [7] LYRA M, CHARALAMBATOU P, ROUSSOU E, et al. Hellenic Journal of Nuclear Medicine, 2011, 14(1):49.
    [8] GAO Feng, LIN Li, LIU Yuhao, et al. Journal of Isotopes, 2012, 21(6):257. (in Chinese) (高峰, 林力, 刘宇昊, 等. 同位素, 2012, 21(6):257.)
    [9] WU Haosong. Foreign Nuclear News, 2011(6):28. (in Chinese) (伍浩松. 国外核新闻, 2011(6):28.)
    [10] LI Mingqi, DENG Qimin, CHENG Zuoyong, et al. Journal of Isotopes, 2013, 26(3):186. (in Chinese) (李明起, 邓启民, 程作用, 等. 同位素, 2013, 26(3):186.)
    [11] PONSARD B. Kernkraftwerke in Deutschland Betriebsergebnisse, 2015, 61(1):41.
    [12] ZOU Wei, YIN Hongyu, LIU Qiong. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2016, 36(4):375. (in Chinese) (邹巍, 尹红玉, 刘琼. 中华核医学与分子影像杂志, 2016, 36(4):375.)
    [13] FILZEN M, ELLINGSON R, PAULSEN M, et al. Journal of Nuclear Medicine Technology, 2017, 45:1.
    [14] Non-HEU Production technologies for molybdenum-99 and technetium-99m[M]. Vienna:IAEA Nuclear Energy Series No.NF-T-5.4. ISBN 978-92-0-137710-4.
    [15] Opportunities and Approaches for Supplying Molybdenum-99 and Associated Medical Isotopes to Global Markets:Proceedings of a Symposium[C]. National Academies of Sciences, Engineering, and Medicine 2018 Washington, DC. The National Academies Press.
    [16] RYABCHIKOV A I, SKURIDIN V S, NESTEROV E V, et al. Nucl Instr and Meth B, 2004, 213(03):364.
    [17] KNAPP F, MIZADEH S. Europe Journal of Nuclear Medical 1994, 21(10):1151.
    [18] The Supply of Medical Radioisotopes:Review of Potential Molybdenum-99/Technetium-99m Production Technologies[M]. Vienna:Nuclear Energy Agency.2010. ISBN:978-92-64-99164-4.
    [19] ZYKOV M, ROMANOVSKⅡ N, WESTER D, et al. Radiochemistry, 2001, 43(3):297.
    [20] BALL R. Medical Isotope Production Reactor[P]. US:5596611,1997.01.21.
    [21] VALENTIN I. Research Reactors in Russia:Status and Prospects for Reducing the Fuel Enrichment, 2010.
    [22] PAVSHOOK V, KHVOSTIONOV V. International Meeting on Reduced Enrichment for Research and Test Reactors. October 18-23, 1998.
    [23] CHUVILIN D, KHVOSTIONOV V, MARKOVSKIJ D, et al. Applied Radiation and Isotopes, 2007, 65(10):1087.
    [24] Homogeneous Aqueous Solution Nuclear Reactors for the Production of Mo-99 and Other Short-lived Radioisotopes[M]. IAEA-TECDOC-1601, Vienna, Austria, September 2008 ISBN:978-92-0-109708-8.
    [25] LI Yunzhao, WU Hongchun, CAO Liangzhi, et al. Nuclear Power Engineering, 2009, 30(6):15.
    [26] DENG Qimin, LI Maoliang, CHENG Zuoyong. Chinese Journal of Nuclear Science and Engineering, 2006, 26(2):165. (in Chinese). (邓启民, 李茂良, 程作用. 核科学与工程, 2006, 26(2):165.)
    [27] CHABOD S, BLANDIN C, CHARTIER F, et al. Nucl Instr and Meth A. 2006, 562(2):618.
    [28] PANEBIANCO S, BEAUVAIS P, BRINGER O, et al. International Conference on Nuclear Data for Science and Technology 2007.
    [29] GREG C. Argonne National Laboratory. 2015.06.15.
    [30] CHEMERISOV S, YOUKER A, HEBDEN A, et al. Mo-99 topical meeting, December 4-7, 2011, New Mexico.
    [31] YOUKER A, CHEMERISOV S, TKAC P. Mo-99 Topical Meeting on Molybdenum-99 Technological Development, September 11-14, 2016, St. Louis, Missouri.
    [32] WU Yican. International Journal of Energy Research, 2017, 42:3572.
    [33] WU Yican, LIU Chao, SONG Gang, et al. Nuclear Science and Engineering, 2016, 36(1):77. (in Chinese) (吴宜灿, 刘超, 宋钢, 等. 核科学与工程, 2016, 36(1):77.
    [34] TKAC P, CHEMERISOV S, MAKARASHVILI V, et al. Mo-992013 Topical Meeting on Molybdenum-99 Technological Development. April 1-5, 2013, Chicago, Illinois.
    [35] FONG A, MEYER T, ZALA K. Task Force on Alternatives for Medical Isotope, October 19-20, 2008, Vancouver.
    [36] BUNATIAN G, NIKOLENKO V, POPOV A. Eprint arXiv:1012.5002, 2009.
    [37] BENNETT R, CHRISTIAN J, PETTI D, et al. Nuclear Technology, 1999, 126(1):102.
    [38] RICHARD V. Nature, 2013, 504(7479):202.
    [39] DALE G, CHEMERISOV S, VANDEGRIFT G, et al. AIP Conference Proceedings. American Institute of Physics, 2013:355.
    [40] WOLOSHUN K, DALE G, KELSEY C. 5th High Power Targetry Workshop, 2013(01):41.
    [41] SCHOLTEN B, LAMBRECHT R, COGNEAU M, et al. Applied Radiation and Isotopes, 1999, 51(1):69.
    [42] TAKACS S, SZUCS Z, TARKANYI F, et al. Journal of Radioanalytical and Nuclear Chemistry. 2003, 257(1):195.
    [43] GUERIN B, SEBASTIEN T, RODRIGUE S, et al. Journal of Nuclear Medicine, 2010, 51(4):13N.
    [44] Medical Isotope Production Without Highly Enriched Uranium[M]. Washington DC:National Academies Press, 2009.
    [45] SCHAFFER P, BENARD F, BERNSTEIN A, et al. Physics Procedia. 2015(66):383.
    [46] Nuclear Technology Review[M]. International Atomic Energy Agency, 2010, Vienna, Austria.
    [47] National Research Council (US) Committee on Medical Isotope Production Without Highly Enriched Uranium. Nonproliferation Review, 2009, 16(2):285.
    [48] XU Xiaofei, MA Hongli. Science & Technology Vision, 2014(22):8. (in Chinese) (许晓飞, 马红利. 科技视界, 2014(22):8.)
    [49] WALT T, COETZEE P. Radiochimical Acta/International Journal for Chemical Aspects of Nuclear Science & Technology, 2004, 92(4-6/2004):251.
    [50] WU D, LANDSBERGER S, VANDEGRIFT G. Office of Scientific & Technical Information Technical Reports, 1996.
    [51] HWANG D, CHOUNG W, KIM Y, et al. Journal of Radioanalytical & Nuclear Chemistry, 2002, 254(2):255.
    [52] WANG Qinggui, LIANG Jixin, WU Yuxuan. Journal of Isotopes, 2016, 29(4):216. (in Chinese) (王清贵, 梁积新, 吴宇轩. 同位素, 2016, 29(4):216.)
    [53] CHEMERISOV S, YOUKER A, HEBDEN, et al. Molybdenum-99 Topical Meeting. New Mexico December 4-7, 2011 La Fonda Hotel Santa Fe.
    [54] YOUKER A, CHEMERISOV S, TKAC P, et al. Journal of Nuclear Medicine Official Publication Society of Nuclear Medicine, 2016, 58(3):514.
    [55] YOUKER A, CHEMERISOV S, TKAC P. Mo-992016 Topical Meeting on Molybdenum-99 Technological Development. Sep11-14, 2016 St. Louis, Missouri.
    [56] MARTINI P, BOSCHI A, CICORIA G, et al. Applied Radiation and Isotopes, 2016, 118:302.
    [57] BOSCHI A, MARTINI P, PASQUALI M, et al. Drug Development and Industrial Pharmacy, 2017:1.
    [58] WU haosong. Foreign Nuclear News, 2016(4):1. (in Chinese) (伍浩松. 国外核新闻, 2016(4):1.)
  • 加载中
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Article Metrics

Article views(3260) PDF downloads(404) Cited by()

Proportional views

Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc

doi: 10.11804/NuclPhysRev.36.02.170
Funds:  National Natural Science Foundation of China (11605232); Anhui Provincial Natural Science Foundation (1808085MA10)

Abstract: Currently the 99mTc is most widely used medical radioisotope as a tracer in clinical diagnosis. The supply of the 99mTc mainly depends on the production of the 99Mo in the research reactors by irradiating High Enriched Uranium targets. The traditional production technique has disadvantages of complex process, high cost, long-distance transportation loss and the risk of nuclear weapons proliferation, etc. In addition, the number of research reactors and processing facilities are limited and most of the facilities will be decommissioned soon. Sometime the supply of 99Mo/99mTc has a problem due to unexpected reactor shutdown or planned maintenance. So, during recent years, a variety of new production techniques, such as the methods using facilities of linear/cyclotron accelerators and new types of reactors, have been proposed to restore the stable supply of 99Mo/99mTc. Starting from the current supply and demand situation of 99Mo/99mTc, this paper analyses the main problems existing in the current supply chain, and mainly introduces the principle, research progress and economic benefits of six traditional and new production technologies of 99Mo/99mTc. Following three separation and purification processes of 99Mo/99mTc, the development trend and prospect of 99Mo/99mTc production were discussed. Among them, the technology of accelerator-driven fission low-enriched-uranium solution is the key research direction in the future for no reactor, no high-enriched uranium, less radioactive waste. It is also imperative to develop and optimize the separation and purification process suitable for the production system in order to reduce the loss of 99Mo/99mTc and improve product quality. The theoretical output of the99Mo sub-critical production system driven by the deuterium-tritium fusion neutron source, designed by the Institute of Nuclear Safety Technology of the Chinese Academy of Sciences, is 27 Ci/day, which can meet the medical diagnostic needs of a province in China.

LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
Citation: LI Ziwei, HAN Yuncheng, WANG Xiaoyu, ZHANG Jiachen, WANG Yongfeng, HUANG Qunying. Production Status and Technical Prospects of Medical Radioisotope 99Mo/99mTc[J]. Nuclear Physics Review, 2019, 36(2): 170-183. doi: 10.11804/NuclPhysRev.36.02.170
Reference (58)

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return